Structural and enzymatic analyses reveal the binding mode of a novel series of francisella tularensis enoyl reductase (FabI) inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 12, 2012, Pages 5933-5941

  Mehboob, Shahila ^a   Hevener, Kirk E ^a   Truong, Kent ^a   Boci, Teuta ^a   Santarsiero, Bernard D ^a   Johnson, Michael E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CONFORMATION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME SUBSTRATE; FRANCISELLA TULARENSIS; IC 50; INHIBITION KINETICS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; CATALYTIC DOMAIN; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; FRANCISELLA TULARENSIS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, MOLECULAR; NAD; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863109105     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300489v     Document Type: Article

References (47)

1. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48, 1-12
2. Lu, H.; Tonge, P. J. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway Acc. Chem. Res. 2008, 41, 11-20
3. Bergler, H.; Fuchsbichler, S.; Hogenauer, G.; Turnowsky, F. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA Eur. J. Biochem. 1996, 242, 689-694
4. White, S. W.; Zheng, J.; Zhang, Y. M. Rock. The structural biology of type II fatty acid biosynthesis Annu. Rev. Biochem. 2005, 74, 791-831
5. Miesel, L.; Greene, J.; Black, T. A. Genetic strategies for antibacterial drug discovery Nature Rev. 2003, 4, 442-456
6. Heath, R. J.; Rock, C. O. A triclosan-resistant bacterial enzyme Nature 2000, 406, 145-146
7. Heath, R. J.; Su, N.; Murphy, C. K.; Rock, C. O. The enoyl-[acyl-carrier- protein] reductases FabI and FabL from Bacillus subtilis J. Biol. Chem. 2000, 275, 40128-40133
8. Massengo-Tiasse, R. P.; Cronan, J. E. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase J. Biol. Chem. 2008, 283, 1308-1316
9. Marrakchi, H.; Dewolf, W. E., Jr.; Quinn, C.; West, J.; Polizzi, B. J.; So, C. Y.; Holmes, D. J.; Reed, S. L.; Heath, R. J.; Payne, D. J.; Rock, C. O.; Wallis, N. G. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK) Biochem. J. 2003, 370, 1055-1062
10. Lu, H.; England, K.; am Ende, C.; Truglio, J. J.; Luckner, S.; Reddy, B. G.; Marlenee, N. L.; Knudson, S. E.; Knudson, D. L.; Bowen, R. A.; Kisker, C.; Slayden, R. A.; Tonge, P. J. Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity ACS Chem. Biol. 2009, 4, 221-231
11. England, K.; am Ende, C.; Lu, H.; Sullivan, T. J.; Marlenee, N. L.; Bowen, R. A.; Knudson, S. E.; Knudson, D. L.; Tonge, P. J.; Slayden, R. A. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia J. Antimicrob. Chemother. 2009, 64, 1052-1061
12. Balemans, W.; Lounis, N.; Gilissen, R.; Guillemont, J.; Simmen, K.; Andries, K.; Koul, A. Essentiality of FASII pathway for Staphylococcus aureus Nature 2010, 463, E3; discussion E4
13. Brinster, S.; Lamberet, G.; Staels, B.; Trieu-Cuot, P.; Gruss, A.; Poyart, C. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens Nature 2009, 458, 83-86
14. Brinster, S.; Lamberet, G.; Staels, B.; Trieu-Cuot, P.; Gruss, A.; Poyart, C.; Brinster reply Nature 2010, 463, E4-E5
15. Parsons, J. B.; Frank, M. W.; Subramanian, C.; Saenkham, P.; Rock, C. O. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 15378-15383
16. Raetz, C. R.; Reynolds, C. M.; Trent, M. S.; Bishop, R. E. Lipid A modification systems in gram-negative bacteria Annu. Rev. Biochem. 2007, 76, 295-329
17. Oyston, P. C.; Sjostedt, A.; Titball, R. W. Tularaemia: bioterrorism defence renews interest in Francisella tularensis Nature Rev. 2004, 2, 967-978
18. Hepburn, M. J.; Simpson, A. J. Tularemia: current diagnosis and treatment options Expert Rev. Anti.-Infect. Ther. 2008, 6, 231-240
19. Russell, A. D. Whither triclosan? J. Antimicrob. Chemother. 2004, 53, 693-695
20. Yazdankhah, S. P.; Scheie, A. A.; Hoiby, E. A.; Lunestad, B. T.; Heir, E.; Fotland, T. O.; Naterstad, K.; Kruse, H. Triclosan and antimicrobial resistance in bacteria: an overview Microb. Drug Resist. 2006, 12, 83-90
21. Moir, D. T. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase Curr. Drug Targets Infect. Disord. 2005, 5, 297-305
22. Chhibber, M.; Kumar, G.; Parasuraman, P.; Ramya, T. N.; Surolia, N.; Surolia, A. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli Bioorg. Med. Chem. 2006, 14, 8086-8098
23. Freundlich, J. S.; Anderson, J. W.; Sarantakis, D.; Shieh, H. M.; Yu, M.; Valderramos, J. C.; Lucumi, E.; Kuo, M.; Jacobs, W. R., Jr.; Fidock, D. A.; Schiehser, G. A.; Jacobus, D. P.; Sacchettini, J. C. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4′-substituted triclosan derivatives Bioorg. Med. Chem. Lett. 2005, 15, 5247-5252
24. Freundlich, J. S.; Yu, M.; Lucumi, E.; Kuo, M.; Tsai, H. C.; Valderramos, J. C.; Karagyozov, L.; Jacobs, W. R., Jr.; Schiehser, G. A.; Fidock, D. A.; Jacobus, D. P.; Sacchettini, J. C. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2′-substituted triclosan derivatives Bioorg. Med. Chem. Lett. 2006, 16, 2163-2169
25. Rafi, S. B.; Cui, G.; Song, K.; Cheng, X.; Tonge, P. J.; Simmerling, C. Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase J. Med. Chem. 2006, 49, 4574-4580
26. Sivaraman, S.; Sullivan, T. J.; Johnson, F.; Novichenok, P.; Cui, G.; Simmerling, C.; Tonge, P. J. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues J. Med. Chem. 2004, 47, 509-518
27. Tipparaju, S. K.; Mulhearn, D. C.; Klein, G. M.; Chen, Y.; Tapadar, S.; Bishop, M. H.; Yang, S.; Chen, J.; Ghassemi, M.; Santarsiero, B. D.; Cook, J. L.; Johlfs, M.; Mesecar, A. D.; Johnson, M. E.; Kozikowski, A. P. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase ChemMedChem 2008, 3, 1250-1268
28. Grassberger, M. A.; Turnowsky, F.; Hildebrandt, J. Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues J. Med. Chem. 1984, 27, 947-953
29. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; DeWolf, W. E., Jr.; Elkins, P. A.; Head, M. S.; Jakas, D. R.; Janson, C. A.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Payne, D. J.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Uzinskas, I. N.; Wallis, N. G.; Huffman, W. F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK J. Med. Chem. 2003, 46, 1627-1635
30. Ling, L. L.; Xian, J.; Ali, S.; Geng, B.; Fan, J.; Mills, D. M.; Arvanites, A. C.; Orgueira, H.; Ashwell, M. A.; Carmel, G.; Xiang, Y.; Moir, D. T. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase Antimicrob. Agents Chemother. 2004, 48, 1541-1547
31. Kitagawa, H.; Kumura, K.; Takahata, S.; Iida, M.; Atsumi, K. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI Bioorg. Med. Chem. 2007, 15, 1106-1116
32. Hevener, K. E.; Mehboob, S.; Su, P. C.; Truong, K.; Boci, T.; Deng, J.; Ghassemi, M.; Cook, J. L.; Johnson, M. E. Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching J. Med. Chem. 2012, 55, 268-279
33. Kabsch, W. J. XDS Appl. Crystallogr. 1993, 795-800
34. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674
35. Mehboob, S.; Truong, K.; Santarsiero, B. D.; Johnson, M. E. Crystal structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD(+) and triclosan Acta Crystallogr. 2010, 66, 1436-1440
36. Vagin, A. A.; Steiner, R. A.; Lebedev, A. A.; Potterton, L.; McNicholas, S.; Long, F.; Murshudov, G. N. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use Acta Crystallogr., Sect. D 2004, 60, 2184-2195
37. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D 2010, 66, 486-501
38. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B., III; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 2007, 35, W375-383
39. Rafi, S.; Novichenok, P.; Kolappan, S.; Zhang, X.; Stratton, C. F.; Rawat, R.; Kisker, C.; Simmerling, C.; Tonge, P. J. Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli J. Biol. Chem. 2006, 281, 39285-39293
40. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Heerding, D. A.; Yuan, C. C.; Head, M. S.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; Pearson, S. C.; Berry, V.; DeWolf, W. E., Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Huffman, W. F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI) J. Med. Chem. 2002, 45, 3246-3256
41. He, X.; Alian, A.; Stroud, R.; Ortiz de Montellano, P. R. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis J. Med. Chem. 2006, 49, 6308-6323
42. Stewart, M. J.; Parikh, S.; Xiao, G.; Tonge, P. J.; Kisker, C. Structural basis and mechanism of enoyl reductase inhibition by triclosan J. Mol. Biol. 1999, 290, 859-865
43. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
44. Hernandes, M. Z.; Cavalcanti, S. M.; Moreira, D. R.; de Azevedo Junior, W. F.; Leite, A. C. Halogen atoms in the modern medicinal chemistry: hints for the drug design Curr. Drug Targets 2010, 11, 303-314
45. Lu, Y.; Shi, T.; Wang, Y.; Yang, H.; Yan, X.; Luo, X.; Jiang, H.; Zhu, W. Halogen bonding - a novel interaction for rational drug design? J. Med. Chem. 2009, 52, 2854-2862
46. Baldock, C.; Rafferty, J. B.; Sedelnikova, S. E.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Hawkes, T. R.; Rice, D. W. A mechanism of drug action revealed by structural studies of enoyl reductase Science 1996, 274, 2107-2110
47. Heerding, D. A.; Chan, G.; DeWolf, W. E.; Fosberry, A. P.; Janson, C. A.; Jaworski, D. D.; McManus, E.; Miller, W. H.; Moore, T. D.; Payne, D. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Smith, W.; Takata, D. T.; Vaidya, K. S.; Yuan, C. C.; Huffman, W. F. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI) Bioorg. Med. Chem. Lett. 2001, 11, 2061-2065